Foley & Lardner breaks down the October 28 policy covering BPC-157, TB-500, Semax and three others. Comments are open until November 13, and HHS says it may revisit the policy.
Recap by typeshit. Full story at Foley & Lardner LLP.
Lincoln Journal Star reports FDA advisors are weighing whether seven unapproved peptides can be used in some compounded prescriptions.
The segment covers a federal draft policy that could open access to some injectable peptides, alongside proposed changes to infant formula nutrients.
The longevity researcher argues the FDA system has grown too slow and costly, saying it favors big drugmakers. He offers this as the reason reform efforts emerged.
TikTok's health content rules bar weight-management claims and GLP-1 promos, with removals or account penalties for creators who break them.
2:21
The Las Vegas station covers Lilly's experimental retatrutide and why researchers see it as a potential step up in weight loss.
The linked piece looks at what adding a GLP-1 receptor agonist could mean for the kidneys of patients already taking lithium.
Loading…